EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression

Wataru Kuroki iD, Akihiro Kitadate iD, Yuto Takahashi iD, Sayaka Iwama, Masahiro Yamada, Takahiro Kobayashi iD, Sho Ikeda iD, Kentaro Narita iD, Kosei Matsue iD, Naoto Takahashi

British Journal of Haematology · 2025-06 · 206 (6) · 1615-1626

DOI: 10.1111/bjh.20106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 22.04.2025. Verfasst von Wataru Kuroki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, Receptors, Interleukin-6, Chromosomes, Human, Pair 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japanese Society of Myeloma Research Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab. We aimed to explore the mechanism of daratumumab resistance in 1q+ MM. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM. Next, we focused on the interleukin‐6 receptor (IL6R) located in the 1q21 region because a previous report shows that interleukin‐6 (IL‐6) reduces CD38 expression via the IL‐6/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway activation in MM. Indeed, IL6R expression was significantly higher in 1q+ MM than in 1q WT MM. We verified that the 1q+ human myeloma cell lines (HMCLs) expressed higher IL6R levels than the 1q WT HMCLs. IL‐6 treatment induced CD38 downregulation in both the 1q+ HMCLs and primary bone marrow (BM) samples but not in their 1q WT HMCLs and BM samples. IL‐6 also resulted in the upregulation of phosphorylated STAT3 in 1q+ HMCLs but not in the 1q WT HMCLs. Furthermore, inhibition of the IL‐6/JAK/STAT pathway by treatment with ruxolitinib or tocilizumab restored CD38 expression in the 1q+ HMCLs and BM samples. These findings elucidate the mechanisms underlying daratumumab resistance in 1q+ MM and provide insights for future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaADP-ribosyl Cyclase 1Receptors, Interleukin-6Chromosomes, Human, Pair 1Membrane GlycoproteinsGene Expression Regulation, NeoplasticGene AmplificationNeoplasm ProteinsHumansInterleukin-6Antibodies, MonoclonalCell Line, TumorSTAT3 Transcription FactorMaleFemaleDrug Resistance, NeoplasmMiddle Aged

Stichwörter der Autor:innen

CD38IL‐6/JAK/STAT pathwaychromosome 1q gaindaratumumabmultiple myeloma

Substanzen

ADP-ribosyl Cyclase 1Receptors, Interleukin-6Interleukin-6CD38 protein, humandaratumumabAntibodies, MonoclonalIL6R protein, humanMembrane GlycoproteinsSTAT3 Transcription FactorNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Life Science, Graduate School of Engineering Science, Akita University, Akita, Japan.
  • Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.

ORCID-Profile: Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue

Förderung

  • Japan Society for the Promotion of Science
  • Japanese Society of Myeloma Research Award

Zitieren

APA

Kuroki, W., Kitadate, A., Takahashi, Y., Iwama, S., Yamada, M., Kobayashi, T., Ikeda, S., Narita, K., Matsue, K., & Takahashi, N. (2025). Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression. British Journal of Haematology, 206(6), 1615-1626. https://doi.org/10.1111/bjh.20106

Vancouver

Kuroki W, Kitadate A, Takahashi Y, Iwama S, Yamada M, Kobayashi T, et al. Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression. British Journal of Haematology. 2025;206(6):1615-1626. doi:10.1111/bjh.20106

BibTeX
@article{Kuroki2025,
  author = {Kuroki, Wataru and Kitadate, Akihiro and Takahashi, Yuto and Iwama, Sayaka and Yamada, Masahiro and Kobayashi, Takahiro and Ikeda, Sho and Narita, Kentaro and Matsue, Kosei and Takahashi, Naoto},
  title = {Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {6},
  pages = {1615--1626},
  doi = {10.1111/bjh.20106}
}
Kostenlos starten →